Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

Next Previous
Trial Profile

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelacarsen (Primary)
  • Indications Aortic valve stenosis; Calcinosis
  • Focus Therapeutic Use
  • Acronyms Lp(a)FRONTIERS CAVS
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 01 Apr 2025 Planned End Date changed from 3 Jan 2029 to 12 Mar 2030.
  • 01 Apr 2025 Planned primary completion date changed from 3 Jan 2029 to 12 Mar 2030.
  • 25 Apr 2024 Planned End Date changed from 26 Dec 2028 to 3 Jan 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top